Effect of a polysaccharide‐rich hydrolysate from <i>Saccharomyces cerevisiae</i> (<scp>LipiGo</scp>®) in body weight loss: randomised, double‐blind, placebo‐controlled clinical trial in overweight and obese adults

Santas, Jonathan; Lázaro, Elisabet; Cuñé, Jordi

doi:10.1002/jsfa.8301

Cited by 15 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean trial duration was 17 weeks (range 4–52 weeks) and mean study size was 79 participants (range 12–250). The studies were conducted in New Zealand [37], the United Kingdom [23], the United States [38,39], Canada [31,40], Italy [29,30], Japan [26], Germany [6,30], Mexico [32], Singapore [41] and Spain [33].…”

Section: Resultsmentioning

confidence: 99%

“…Various clinical trials have been performed in the past 25 years investigating the effect of chitosan on body weight, body mass index (BMI), lipid parameters, blood pressure, glucose levels and other health characteristics [6,29,30,31,32,33]. The last meta-analysis quantifying these studies (the Cochrane systematic review of Jull 2008) concluded that these effects were probably not of clinical significance [34].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure

et al. 2018

View full text Add to dashboard Cite

Background and objectives: Erratic results have been published concerning the influence of the dietary supplement chitosan used as a complementary remedy to decrease the body weight of overweight and obese people. The published articles mention as secondary possible benefits of usage of chitosan the improvement of blood pressure and serum lipids status. We performed a meta-analysis evaluating body weight, body mass index, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, systolic and diastolic blood pressure among overweight and obese patients. Materials and Methods: Searching MEDLINE, Cochrane up to December 2017 on clinical trials that have assessed the influence of chitosan used as a dietary supplement on overweight and obese patients. An additional study was identified in the References section of another meta-analysis. A total of 14 randomised control trials (RCT) were used to assess the effect on body weight, serum lipids and blood pressure. Results: The usage of chitosan as a dietary supplement up to 52 weeks seems to slightly reduce the body weight (−1.01 kg, 95% CI: −1.67 to −0.34). Considering the other parameters studied, the most significant improvement was observed in systolic and diastolic blood pressure: −2.68 mm Hg (95% CI: −4.19 to −1.18) and −2.14 mm Hg (95% CI: −4.14 to −0.14) in favour of chitosan versus a placebo. Conclusions: Based on the meta-analysis realized with 14 RCT we concluded that the usage of chitosan as a dietary supplement can lead to a slight short- and medium-term effect on weight loss and to the improvement of serum lipid profile and cardiovascular factors.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A randomised, double-blind, placebo-controlled clinical trial testing BG from Saccharomyces cerevisiae was performed in overweight and obese subjects (3 g/day) for 12 weeks. Results indicated that daily supplementation was useful for improving body weight and waist circumference, without adverse effects [77]. Meta-analysis evaluating the effect of oat BG intake on glycaemic control of diabetic patients (using only randomized controlled trials) indicated that BG ingestion significantly lowered concentrations in fasting plasma glucose and glycosylated hemoglobin (HbA1c) [78].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of different doses of prebiotic (isolated from Saccharomyces cerevisiae) in comparison to n-3 supplement on glycemic control, lipid profiles and immunological response in diabetic rats

Guilarducci

Marcelino

Konig

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background: The regular intake of fiber generates numerous health benefits. However, the efficacy depends on the duration of consumption and the ingested dose. Studies investigating the optimal dose are of interest to enable the inclusion of fiber in the routine treatment of diabetic patients. Objective: We aimed to evaluate the effects of different doses of β-glucan (BG-isolated from Saccharomyces cerevisiae), in comparison to n-3 supplement, on the inflammatory and metabolic parameters of Wistar rats induced to diabetes by streptozotocin. Methods: Forty animals were randomly divided into six groups receiving 0 mg/kg, 10 mg/kg, 20 mg/kg, or 40 mg/kg BG daily for 4 weeks or fish oil derivative [1000 mg/kg of omega-3 fatty acids (n-3)] for the same period. One additional group was composed of healthy controls. Serum metabolic and immunological parameters were evaluated by colorimetric and ELISA assays respectively. Histopathological analysis of the liver, small intestine and pancreas were also conducted. Significant changes due to BG intake were set into regression models with second-degree fit in order to estimate the optimal BG dose to achieve health benefits. Results: The animals that ingested BG had lower food and water intake (p < 0.05) than the negative control group (0 mg/kg). However, consumption was still elevated in comparison to healthy controls. Blood glucose and serum levels of total cholesterol, LDL-c, and TG (p < 0.05) reduced in comparison to diabetic animals without treatment (better or similar to n-3 group depending on dose), but did not reach normal levels (in comparison to healthy controls). HDL-c was not different (p > 0.05) among all groups. These reductions were already seen with the lowest dose of 10 mg/kg. On average, the serum levels of the hepatic enzymes ALT and AST were 40% and 60% lower in the BG groups in comparison to diabetic animals without treatment (better results than n-3 group). The group receiving 40 mg/kg reached similar values of healthy controls for ALT; whereas the same result occurred from the dose of 10 mg/kg for AST. The ideal dose, estimated from the mean of all metabolic parameters was approximately 30 mg/kg/day. Regarding the

show abstract

“…In that study, body weight and waist circumference were also reduced when compared to Placebo after 3 months of treatment. Importantly, participants were not enrolled in a body weight loss program [ 19 ]. Then, the present study results on body weight and waist circumference reduction support the efficacy of Lipigo ® even when combined with a controlled diet.…”

Section: Discussionmentioning

confidence: 99%

“…Lipigo ® is a polysaccharide-rich fraction containing β-glucan, chitin, and chitosan, obtained by a specific hydrolysis procedure of residual S. cerevisiae from brewery. A previous randomized, double-blind, placebo-controlled small trial demonstrated a statistically significant benefit of Lipigo ® on body weight management in overweight and obese population over 12 weeks [ 19 , 20 ]. In the present study, we sought to replicate the previous findings in a more robust randomized clinical trial, comprising a significantly bigger sample size, a better dietary control, and a longer treatment and follow-up periods.…”

Section: Introductionmentioning

confidence: 99%

Regular Consumption of Lipigo® Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program

et al. 2020

View full text Add to dashboard Cite

Obesity is a global public health problem. Objective: To evaluate the effect of the regular consumption of the product Lipigo® on body weight and rebound effect on overweight/obese subjects undergoing a comprehensive weight loss program. Methods: A randomized, parallel, double-blind, placebo-controlled clinical trial was conducted with male and female subjects presenting a BMI 25–39.9 kg/m2. All subjects underwent a comprehensive weight loss program (WLP) for 12 weeks, which included an individualized hypocaloric diet, physical activity recommendations, nutritional education seminars, and three times a day consumption of the product Lipigo® or Placebo. After-WLP, subjects continued the treatment for 9 months to assess rebound effect. Body weight (BW), BMI, and body composition were measured at the beginning and the end of the WLP, and in the follow-up. Results: A total of 120 subjects (85% women) 49.0 ± 9.5 years old and with a BW of 81.57 ± 13.26 kg (BMI 31.19 ± 3.44 kg/m2) were randomized and 73 subjects finished the study. At the end of the WLP, there was a tendency toward reduced BW (p = 0.093), BMI (p = 0.063), and WC (p = 0.059) in the treated group. However, subjects with obesity type 1 (OB1) from the treated group significantly reduced body weight (−5.27 ± 2.75 vs. −3.08 ± 1.73 kg; p = 0.017) and BMI (−1.99 ± 1.08 vs. −1.09 ± 0.55 kg/m2; p = 0.01) compared with placebo. They also presented a minor rebound effect after 9 months with product consumption (−4.19 ± 3.61 vs. −1.44 ± 2.51 kg; p = 0.026), minor BMI (−1.61 ± 1.43 vs. −0.52 ± 0.96 kg/m2; p = 0.025) and tended to have less fat-mass (−3.44 ± 2.46 vs. −1.44 ± 3.29 kg; p = 0.080) compared with placebo. Conclusions: The regular consumption of the product Lipigo® promotes the reduction of body weight and reduces the rebound effect of obese people after 52 weeks (12 months), mainly in obesity type 1, who undergo a comprehensive weight loss program.

show abstract

Effect of a polysaccharide‐rich hydrolysate from Saccharomyces cerevisiae (LipiGo®) in body weight loss: randomised, double‐blind, placebo‐controlled clinical trial in overweight and obese adults

Cited by 15 publications

References 24 publications

A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure

A Meta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure

Therapeutic effects of different doses of prebiotic (isolated from Saccharomyces cerevisiae) in comparison to n-3 supplement on glycemic control, lipid profiles and immunological response in diabetic rats

Regular Consumption of Lipigo® Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program

Contact Info

Product

Resources

About